Topic: How To Invest

Q: Pat: May I have your views on Covalon Technologies. Thank you.

Article Excerpt

A: Covalon Technologies Ltd., $7.98, symbol COV on the Toronto Venture Exchange (Shares outstanding: 19.4 million; Market cap: $160.5 million; www.covalon.com), develops advanced-care products for the treatment of a wide range of wounds; it also manufactures infection-prevention products such as MediClear PreOp. It’s a breathable, transparent, self-adhesive, silicone barrier film that conforms to the contours of the body. Covalon generates its revenue through development and distribution contracts, licensing agreements and product sales. The stock jumped in early-May 2018 following the company’s announcement it had won a series of competitive contracts in the Middle East. Those deals have an estimated value of $100 million over three years. The agreements call for the delivery of products across ten categories. That includes Covalon’s IV Clear, ColActive Plus, and CovaWound product lines. A major client is the Executive Board of Health Ministers’ Council for Gulf Cooperation Council States (SGH), although private organizations in Saudi Arabia and other regional markets are also represented. In the three months ended June…